key: cord-0911551-js7qzk4q authors: Jermain, Brian; Hanafin, Patrick O.; Cao, Yanguang; Lifschitz, Adrian; Lanusse, Carlos; Rao, Gauri title: Development of a minimal physiologically-based pharmacokinetic model to simulate lung exposure in humans following oral administration of ivermectin for COVID-19 drug repurposing date: 2020-09-04 journal: J Pharm Sci DOI: 10.1016/j.xphs.2020.08.024 sha: 1c0ff3218c3b4dd99ac8f121994cfb5ed37579ab doc_id: 911551 cord_uid: js7qzk4q SARS-CoV-2 utilizes the IMPα/β1 heterodimer to enter host cell nuclei after gaining cellular access through the ACE2 receptor. Ivermectin has shown antiviral activity by inhibiting the formation of the importin-α (IMPα) and IMPβ1 subunits as well as dissociating the IMPα/β1 heterodimer and has in vitro efficacy against SARS-CoV-2. Plasma and lung ivermectin concentrations vs. time profiles in cattle were used to determine the apparent plasma to lung tissue partition coefficient of ivermectin. This coefficient, together with a simulated geometric mean plasma profile of ivermectin from a published population pharmacokinetic model, was utilized to develop a minimal physiologically-based pharmacokinetic (mPBPK) model. The mPBPK model accurately described the simulated ivermectin plasma concentration profile in humans. The mPBPK model was also used to simulate human lung exposure to ivermectin after 12, 30, and 120 mg oral doses. The simulated ivermectin lung exposures reached a maximum concentration of 772 ng/mL, far less than the estimated 1750 ng/mL IC50 reported for ivermectin against SARS-CoV-2 in vitro. Further studies of ivermectin either reformulated for inhaled delivery or in combination with other antivirals with differing mechanisms of action is needed to assess its therapeutic potential. The novel SARS-CoV-2 coronavirus causes COVID-19 and has caused a global pandemic resulting in 36 over twenty-four million infections and eight hundred thousand deaths at the time of writing. Healthcare 37 providers and researchers are currently repurposing approved drugs in an attempt to treat 38 patients as urgent efforts to develop effective vaccines and treatments continue. SARS-CoV-2 causes infection through entering host cells by binding to angiotensin-converting enzyme 2 40 (ACE2) receptors, which are present in many tissues but predominantly human alveolar epithelial cells. Ivermectin is an approved human and animal anthelmintic which has also shown antiviral properties. Ivermectin inhibits the formation of the importin-α (IMPα) and IMPβ1 subunits as well as causes the 43 dissociation of the formed IMPα/β1 heterodimer. [3] [4] [5] [6] [7] The IMPα/β1 heterodimer is thought to be used by the 44 SARS-CoV-2 nucleoprotein to infiltrate the nucleus, thereby delaying cellular proliferation and 45 establishing an optimal environment inside the host cell for virus assembly and replication. Model estimates and precision (CV%) for K a , CL p /F, Fraction, K p, other /F, and K tr are shown in Table 1 . Parameter precision around data-informed parameters such as K a and CL p /F were below 5%. The Human lung exposure simulations following oral administration of 120 mg ivermectin are shown in Figure 127 3A while the plasma profile is shown in Figure 3B . Profiles for human plasma and lung exposure 128 simulations resulting from 12 and 30 mg doses are shown in Figure S1 in the supplementary material. The maximum simulated ivermectin concentrations in plasma and lung were 288 and 772 ng/mL Ivermectin is a compelling candidate for consideration as part of a combination regimen by making the 150 host cell environment unfavorable for SARS-CoV-2 assembly and replication after IMPα/β1 heterodimer 151 dissociation and inhibition. [8] [9] [10] Ivermectin is also lipophilic with a pK a >8, which has been shown to be 152 beneficial for uptake into the lungs from plasma (Figure 3) . 20 We hypothesize that ivermectin in 153 combination with other agents of differing antiviral mechanisms of action could be efficacious and/or 154 reduce the ivermectin exposure necessary to eradicate SARS-CoV-2 through synergistic effects. Although our model development and approach is unique compared to current literature, our results and 156 conclusions are in agreement with previous analysis in regards to iveremctin's potential as a COVID-19 157 therapeutic agent. 18, 19 Our efforts are different in that we have provided a framework for mPBPK model 158 development that can be utilized for any future compound thought to be a potential treatment option for 159 COVID-19. Also, by providing the differential equations, future investigators will not be limited by the 160 modeling software/tool available to them and will be able to implement this mPBPK model structure. Our The main limitations of our approach are the inability to validate our simulated human lung exposure with any published values as well as not being able to simulate drug accumulation in tissue after multiple 165 J o u r n a l P r e -p r o o f dosing. Ivermectin is highly protein bound (~93%), and the proposed simulation represents the total ivermectin concentration. 17, 21 Total ivermectin concentrations were simulated because protein binding in 167 the lung has not been assessed, but it is likely the free drug concentration is significantly lower than the 168 772 ng/mL peak lung concentration simulated which reinforces the need for an inhalational dose. Ruminants such as cattle have similarly high plasma binding compared to humans (96-99%), and total 170 ivermectin concentration was assessed by Lifschitz and colleagues. 12, 22 Also, because of the similarity in 171 plasma binding of ivermectin between species, the K p,lung /F was considered species-independent due to Angiotensin-converting enzyme 2 198 is a functional receptor for the SARS coronavirus Tissue distribution of ACE2 200 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis Inhibitors of nuclear transport Ivermectin: enigmatic multifaceted 'wonder' drug continues to surprise and exceed 205 expectations Ivermectin is a specific inhibitor of 207 importin alpha/beta-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus Nuclear localization of 210 dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the 211 inhibitor Ivermectin The broad spectrum 213 antiviral ivermectin targets the host nuclear transport importin alpha/beta1 heterodimer Nuclear/nucleolar localization properties of 216 C-terminal nucleocapsid protein of SARS coronavirus The coronavirus infectious 220 bronchitis virus nucleoprotein localizes to the nucleolus The FDA-approved drug ivermectin inhibits 222 the replication of SARS-CoV-2 in vitro The effect of 226 azithromycin on ivermectin pharmacokinetics--a population pharmacokinetic model analysis Normal organ weights in men: part II-the brain, lungs, liver, spleen, and 229 kidneys Medical Physiology E-Book Safety, tolerability, 232 and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects The pharmacokinetics and interactions of ivermectin in humans--a mini-review The Approved Dose of Ivermectin Alone is not the Ideal Dose 238 for the Treatment of COVID-19 Ivermectin and COVID-19: A report in Antiviral 240 Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses. 241 Antiviral research Drug handling by the lungs Ivermectin binds avidly to plasma proteins Macrocyclic lactones: distribution in plasma lipoproteins of 246 several animal species including humans Applications of minimal physiologically-based pharmacokinetic models Basic concepts in physiologically based pharmacokinetic modeling in 251 drug discovery and development